Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 4,357.6% in February

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 2,677,258 shares, a growth of 4,357.6% from the January 29th total of 60,060 shares. Based on an average daily volume of 43,066,965 shares, the short-interest ratio is currently 0.1 days. Approximately 8.6% of the shares of the company are sold short. Approximately 8.6% of the shares of the company are sold short. Based on an average daily volume of 43,066,965 shares, the short-interest ratio is currently 0.1 days.

Liminatus Pharma Trading Up 2.8%

NASDAQ:LIMN opened at $0.24 on Thursday. The stock has a 50-day moving average price of $0.72 and a 200 day moving average price of $1.39. The stock has a market capitalization of $7.42 million and a P/E ratio of -1.99. Liminatus Pharma has a 12-month low of $0.21 and a 12-month high of $33.66.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on LIMN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Liminatus Pharma from a “hold” rating to a “strong sell” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Liminatus Pharma has a consensus rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.